2024
Exploring the Present and Imagining the Future Landscape of Onconephrology
Aklilu A, Shirali A. Exploring the Present and Imagining the Future Landscape of Onconephrology. Kidney360 2024, 5: 1377-1379. PMID: 39186390, PMCID: PMC11441807, DOI: 10.34067/kid.0000000000000544.Peer-Reviewed Original Research
2023
Diffuse Alveolar Hemorrhage Presenting in IgA Nephropathy
Jobson C, Luciano R, Shirali A, Malvar G. Diffuse Alveolar Hemorrhage Presenting in IgA Nephropathy. Journal Of The American Society Of Nephrology 2023, 34: 1119-1119. DOI: 10.1681/asn.20233411s11119a.Peer-Reviewed Original ResearchA Vexing Case
Dave D, Malvar G, Moeckel G, Shirali A. A Vexing Case. Journal Of The American Society Of Nephrology 2023, 34: 249-250. DOI: 10.1681/asn.20233411s1249d.Peer-Reviewed Original ResearchOnconephrology: Core Curriculum 2023
Yarandi N, Shirali A. Onconephrology: Core Curriculum 2023. American Journal Of Kidney Diseases 2023, 82: 743-761. PMID: 37855786, DOI: 10.1053/j.ajkd.2023.04.014.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsKidney diseaseChimeric antigen receptor T cellsAntigen receptor T cellsAJKD's Core CurriculumAcute kidney injuryKidney transplant recipientsChronic kidney diseaseReceptor T cellsKidney injuryTransplant recipientsElectrolyte disordersCell transplantClinical syndromeMonoclonal gammopathyGlomerular diseaseT cellsCancer riskClinical decisionCancer treatmentDiseaseOnconephrologySyndromeCancerSpecific considerationsHypertensionHow Sweet It Is: A Perspective on the Potential Anti-Tumor Role for SGLT2 Inhibitors
Gunasekaran D, Shirali A. How Sweet It Is: A Perspective on the Potential Anti-Tumor Role for SGLT2 Inhibitors. Kidney360 2023, 4: e1322-e1324. PMID: 37487034, PMCID: PMC10550005, DOI: 10.34067/kid.0000000000000219.Commentaries, Editorials and LettersOnco-Nephrology Kidney Disease in the Cancer Patient
Yarandi N, Shirali A. Onco-Nephrology Kidney Disease in the Cancer Patient. Medical Clinics Of North America 2023, 107: 749-762. PMID: 37258012, DOI: 10.1016/j.mcna.2023.03.007.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsKidney diseaseAcute kidney injuryChronic kidney diseaseDifferent clinical manifestationsSubspecialty of nephrologyOnco-NephrologyKidney injuryElectrolyte disturbancesClinical manifestationsCancer patientsGeneral internistsPatientsDiseaseCancerHypertensionProteinuriaInternistsInjuryNephrologyImmune Checkpoint Inhibitors: Immunobiology and Immune-related Adverse Events
Shirali, AC and Karam S. Immune Checkpoint Inhibitors: Immunobiology and Immune-related Adverse Events. In the American Society of Nephrology Onco-nephrology Curriculum. Eds. Letcha, S and N Leung. 2023. Available on-line at https://education.asn-online.org/course/view.php?id=1205&pageid=2815Peer-Reviewed Educational MaterialsChemotherapy-Associated Thrombotic Microangiopathy
Aklilu A, Shirali A. Chemotherapy-Associated Thrombotic Microangiopathy. Kidney360 2023, 4: 409-422. PMID: 36706238, PMCID: PMC10103319, DOI: 10.34067/kid.0000000000000061.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsDrug-induced thrombotic microangiopathyThrombotic microangiopathyPlasma exchangePrimary atypical hemolytic uremic syndromeAtypical hemolytic uremic syndromeEnd-organ dysfunctionMicroangiopathic hemolytic anemiaSecondary thrombotic microangiopathyTherapeutic plasma exchangeTerminal complement inhibitorLarge multicenter studyHemolytic uremic syndromeRole of complementPotential treatment strategyProteinuria reductionSupportive careBlood pressureMulticenter studyTreatment courseUremic syndromeComplement inhibitionTreatment strategiesHemolytic anemiaAntiangiogenesis agentsComplement inhibitors
2022
Collagenofibrotic Glomerulopathy in a Patient With Waldenstrom Macroglobulinemia
Gunasekaran D, Shirali A. Collagenofibrotic Glomerulopathy in a Patient With Waldenstrom Macroglobulinemia. Journal Of The American Society Of Nephrology 2022, 33: 168-168. DOI: 10.1681/asn.20223311s1168a.Peer-Reviewed Original ResearchHiding in Plain Sight: Normotensive Scleroderma Renal Crisis
Chacko E, Shirali A. Hiding in Plain Sight: Normotensive Scleroderma Renal Crisis. Journal Of The American Society Of Nephrology 2022, 33: 612-613. DOI: 10.1681/asn.20223311s1612d.Peer-Reviewed Original ResearchIs Rechallenge Appropriate in Patients that Develop Immune Checkpoint Inhibitor-Associated AKI?: COMMENTARY
Shirali AC. Is Rechallenge Appropriate in Patients that Develop Immune Checkpoint Inhibitor-Associated AKI?: COMMENTARY. Kidney360 2022, 3: 806-808. PMID: 36129422, PMCID: PMC9438420, DOI: 10.34067/kid.0005592021.Commentaries, Editorials and LettersMortality after acute kidney injury and acute interstitial nephritis in patients prescribed immune checkpoint inhibitor therapy
Baker ML, Yamamoto Y, Perazella MA, Dizman N, Shirali AC, Hafez N, Weinstein J, Simonov M, Testani JM, Kluger HM, Cantley LG, Parikh CR, Wilson FP, Moledina DG. Mortality after acute kidney injury and acute interstitial nephritis in patients prescribed immune checkpoint inhibitor therapy. Journal For ImmunoTherapy Of Cancer 2022, 10: e004421. PMID: 35354588, PMCID: PMC8968986, DOI: 10.1136/jitc-2021-004421.Peer-Reviewed Original ResearchConceptsAcute interstitial nephritisAcute kidney injuryImmune checkpoint inhibitor therapyCheckpoint inhibitor therapyICI therapyKidney injuryInhibitor therapyInterstitial nephritisTime-varying Cox proportional hazards modelsHigher peak serum creatinineSevere acute kidney injuryCancer typesCox proportional hazards modelAssociations of biopsyBaseline laboratory valuesObservational cohort studyPeak serum creatinineFavorable treatment responseProportional hazards modelAKI patientsTherapy initiationCohort studySerum creatinineUnivariable analysisImmune activationPathogenesis of Acute Tubulointerstitial Nephritis
Aron A, Krishnan N, Shirali A. Pathogenesis of Acute Tubulointerstitial Nephritis. 2022, 21-47. DOI: 10.1007/978-3-030-93438-5_3.ChaptersAcute tubulointerstitial nephritisImmune systemTubulointerstitial nephritisRecognition of neoantigensHigh blood flowImmune system activationFinal common pathwayProximal tubule cellsRelease of damageInnate immune systemKidney tubulointerstitial fibrosisInflammatory infiltrationTubulointerstitial fibrosisInflammatory pathwaysTubular reabsorptionImmune responseMetabolic insultsReabsorptive capacityBlood flowSystem activationToxin exposureTubule cellsElevated intracellular concentrationsCell damagePathogenesisCancer Drug Dosing in Chronic Kidney Disease and Dialysis
Shirali AC, Sprangers B. Cancer Drug Dosing in Chronic Kidney Disease and Dialysis. Advances In Kidney Disease And Health 2022, 29: 208-216.e1. PMID: 35817528, DOI: 10.1053/j.ackd.2021.12.002.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsChronic kidney diseaseKidney diseaseKidney functionEnd-stage kidney diseasePatient's kidney functionRenal replacement therapyCurrent dosing strategiesClassic chemotherapeutic drugsReplacement therapyDosing strategiesHigh prevalenceDrug dosingKidney metabolismAntineoplastic agentsPharmacokinetic propertiesChemotherapeutic drugsDiseaseSpecific agentsPatientsDosingTherapyDrugsAgentsImmunotherapyMalignancyVenous outflow banding for maturation of a percutaneous arteriovenous fistula
Barahona M, Tonnessen B, Cardella J, Shirali A, Perez-Lozada JC, Chaar C. Venous outflow banding for maturation of a percutaneous arteriovenous fistula. Journal Of Vascular Surgery Cases And Innovative Techniques 2022, 8: 42-44. PMID: 35079669, PMCID: PMC8777140, DOI: 10.1016/j.jvscit.2021.12.007.Peer-Reviewed Case Reports and Technical NotesPathogenesis of Acute Tubulointerstitial Nephritis
Aron, A.W., Krishnan, N., Shirali, A.C. (2022). Pathogenesis of Acute Tubulointerstitial Nephritis. In: Tubulointerstitial Nephritis, Atta, M.G., Perazella, M.A. (eds). Springer, Cham.Chapters
2021
Lysozyme Nephropathy: A Rare Yet Treatable Cause of AKI in Chronic Myelomonocytic Leukemia
Donati A, Shirali A. Lysozyme Nephropathy: A Rare Yet Treatable Cause of AKI in Chronic Myelomonocytic Leukemia. Journal Of The American Society Of Nephrology 2021, 32: 587-588. DOI: 10.1681/asn.20213210s1587d.Peer-Reviewed Original ResearchMiglustat Therapy for SCARB2-Associated Action Myoclonus–Renal Failure Syndrome
Quraishi IH, Szekely AM, Shirali AC, Mistry PK, Hirsch LJ. Miglustat Therapy for SCARB2-Associated Action Myoclonus–Renal Failure Syndrome. Neurology Genetics 2021, 7: e614. PMID: 34337151, PMCID: PMC8320328, DOI: 10.1212/nxg.0000000000000614.Peer-Reviewed Original ResearchAction myoclonus-renal failure syndromeNeurologic symptomsAction myoclonusFailure syndromeProgressive myoclonic epilepsySubstrate reduction therapyWhole-exome sequencingMiglustat therapyAvailable medicationsEarly mortalityReduction therapyMyoclonic epilepsySteady worseningGaucher diseaseMyoclonusGlycosphingolipid metabolismExome sequencingGene mutationsGlucosylceramide accumulationPatientsSeizuresMiglustatSyndromeTherapySymptomsLysozyme nephropathy: A rare and reversible cause of acute kidney injury in chronic myelomonocytic leukemia
Donati A, Luciano R, Shirali A. Lysozyme nephropathy: A rare and reversible cause of acute kidney injury in chronic myelomonocytic leukemia. Journal Of Onco-Nephrology 2021, 5: 120-121. DOI: 10.1177/23993693211026926.Peer-Reviewed Case Reports and Technical Notes
2020
Clinical Features and Outcomes of Immune Checkpoint Inhibitor–Associated AKI: A Multicenter Study
Cortazar FB, Kibbelaar ZA, Glezerman IG, Abudayyeh A, Mamlouk O, Motwani SS, Murakami N, Herrmann SM, Manohar S, Shirali AC, Kitchlu A, Shirazian S, Assal A, Vijayan A, Renaghan AD, Ortiz-Melo DI, Rangarajan S, Malik AB, Hogan JJ, Dinh AR, Shin DS, Marrone KA, Mithani Z, Johnson DB, Hosseini A, Uprety D, Sharma S, Gupta S, Reynolds KL, Sise ME, Leaf DE. Clinical Features and Outcomes of Immune Checkpoint Inhibitor–Associated AKI: A Multicenter Study. Journal Of The American Society Of Nephrology 2020, 31: 435-446. PMID: 31896554, PMCID: PMC7003302, DOI: 10.1681/asn.2019070676.Peer-Reviewed Original ResearchConceptsExtrarenal immune-related adverse eventsImmune-related adverse eventsMulticenter studyRenal prognosisKidney recoveryAdverse eventsMost patientsClinical featuresCombination immune checkpoint inhibitor therapyImmune checkpoint inhibitor initiationImmune checkpoint inhibitor rechallengeImmune checkpoint inhibitor therapyProton pump inhibitor useComplication of immunotherapyLower baseline eGFRNew dialysis requirementWorse renal prognosisCheckpoint inhibitor therapyImmune checkpoint inhibitorsCheckpoint inhibitor initiationBaseline eGFRSubnephrotic proteinuriaCheckpoint inhibitorsDialysis requirementControl patients